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MicroRNAThe activation of IFN-α signaling in B cells contributes to the pathogenesis of systemic lupus erythematosus
(SLE). Many studies suggest that estrogens are closely related to the gender difference in the prevalence of
SLE. However, the underlying mechanism of the interaction between estrogens and the activation of IFN-α sig-
naling in SLE B cells remains incompletely understood. In the present study, we ﬁrst found that healthy female
mice showed an up-regulated type I IFN-induced gene signature in B cells compared with age-matched male
mice, and an in vivo study revealed that the gender difference was related to 17β-estradiol. Moreover, we
found that 17β-estradiol could enhance the activation of IFN-α signaling in an ERα-dependent manner by
down-regulating the expression of three microRNAs, including let-7e-5p, miR-98-5p and miR-145a-5p. These
microRNAs could target the 3′UTR of the IKKε-encoding gene IKBKE directly and regulate the expression of
IKKε, which can promote the activation of IFN-α signaling. In addition, compared with age-matched male
mice, female mice showed a higher level of IKKε and lower levels of let-7e-5p, miR-98-5p and miR-145a-5p in
B cells. Moreover, peripheral blood mononuclear cells from women showed a higher level of IKKε and lower
levels of let-7e-5p, miR-98-5p and miR-145a-5p compared with those from age-matched men. These data
suggest that 17β-estradiol ampliﬁes the activation of IFN-α signaling in B cells via IKKε by down-regulating
the expression of let-7e-5p,miR-98-5p andmiR-145a-5p. Our ﬁndingsmay provide a newperspective for under-
standing the mechanism underlying the gender difference in the prevalence of SLE.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Females are more susceptible to systemic lupus erythematosus
(SLE) than males [1–3]. It is generally accepted that this gender
difference is related to sex chromosomes, sex hormones and other
sex-biased factors. For instance, the course of SLE is accompanied by
ﬂuctuations in the sex hormonal state in women [4–6]. Estrogens can
trigger disease onset and exacerbate the SLE course [7,8], and in partic-
ular, induce a lupus-type phenotype in non-autoimmune disease-prone
mice [9,10].
Multiple studies have shown that estrogens can affect the activation
and function of B cells, T cells, dendritic cells, monocytes and other
immune cells [11–13]. Of note, B cells play a central role in the-α, interferon-α; TLR, Toll like
inaseepsilon;UTR,untranslated
β, small interfering RNA speciﬁc
randactivatorof transcription1
iversity, Nanjing 210093, China.pathogenesis of SLE through the production of pathogenic autoanti-
bodies, the activation of autoreactive T cells, the production of pro-
inﬂammatory cytokines and the organization of ectopic lymphoid tissue
[14–19]. Toll-like receptors (TLRs), particularly TLR7 and TLR9, are also
critically involved in these processes [20,21]. Previous studies have
shown that estrogens can enhance TLR expressions in peritoneal leuko-
cytes and residentmacrophages [22].Moreover, estrogens can affect the
maturation and function of B cells [23,24]. All of these data indicate that
estrogens may regulate TLR expressions and the activation of TLR-
mediated signaling pathways in B cells.
As is well known, interferon-α (IFN-α) has been identiﬁed as a crit-
ical cytokine in the pathogenesis of SLE [25,26]. IFN-α can induce and
accelerate the SLE symptoms in patients and mice [27,28]. Importantly,
IFN-α can impact the function of B cells through a variety of mecha-
nisms, including TLR7 expression, survival and differentiation [29–34].
What's more, immune cells, including B cells, display an up-regulated
IFN-I-induced gene signature in SLE patients [35–42]. Several recent
studies have demonstrated that estrogens can promote the TLR7- and
TLR9-ligand-induced production of IFN-α in pDCs [43,44]. However, it
remains unknown whether estrogens can regulate the activation of
IFN-α signaling in B cells.
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nonical IκB kinase, can promote IFN-I signaling by promoting the
phosphorylation of STAT1 [45]. IKKεwas recently found to be associated
with some autoimmune diseases [46,47]. Although new SLE-associated
sequence variants in IKBKE have been identiﬁed as risk loci for SLE [46,
47], the biological function of IKKε in SLE remains poorly understood. It
is also unknown whether and how estrogens regulate IKKε expression
and the activation of IFN-α-induced JAK1-STAT1 signaling in B cells.
Numerous studies have shown that microRNAs (miRNAs) are in-
volved in themodulation function of estrogens on the immune response
and inﬂammatory processes [48,49]. The dysregulation of miRNAs
participates in the prevalence of autoimmune diseases, including SLE
[50,51]. In particular, there are sex-based differences in the expression
of miRNAs in mouse and rat [52,53]. Interestingly, several studies have
shown that estrogens can regulate the expression of various miRNAs,
such as miR-146a-5p, miR-125a-5p, miR-125b-5p, miR-143-3p, miR-
145a-5p, let-7e-5p, miR-126 and miR-181a-2, in many cell types [48,
54,55].
In past studies, we have found signiﬁcant gender differences in the
global gene expression proﬁles in B cells and revealed that these gender
differences are related to estrogens [56]. In the present study, we found
an up-regulated IFN-I-induced gene signature in B cells from female
mice comparedwith age-matchedmalemice.Moreover, the fundamen-
tal gender difference was related to 17β-estradiol. 17β-Estradiol ampli-
ﬁed the IFN-α-induced activation of JAK1-STAT1 signaling in B cells via
IKKε by down-regulating the expression of let-7e-5p, miR-98-5p and
miR-145a-5p. Furthermore, comparedwith age-matchedmalemice, fe-
male mice showed a higher level of IKKε and lower levels of let-7e-5p,
miR-98-5p andmiR-145a-5p in B cells. Interestingly, a similar phenom-
enon was also existent in peripheral blood mononuclear cells (PBMCs)
from women and age-matched men. Together, these data demonstrate
that 17β-estradiol ampliﬁes the activation of IFN-α signaling via
miRNA-dependent pathways in B cells. Our ﬁndings provide a new per-
spective for understanding themechanism of sex bias in the prevalence
of SLE.
2. Materials and methods
2.1. Mice
Female and male C57BL/6 mice, 4–6 weeks old, were obtained from
Model Animal Research Center at Nanjing University and maintained
under speciﬁc pathogen-free conditions. Female C57BL/6mice, ovariec-
tomized at 4-week-old, were also obtained from Model Animal
Research Center at Nanjing University. All experiments were conducted
in accordance with institutional guidelines for animal care and used
based on the Guide for the Animal Care Committee at Nanjing
University.
2.2. Puriﬁcation of murine splenic B cells and cell culture
Lymphocytes of spleenwere isolated by Ficoll density centrifugation
according to standard procedures. Murine splenic B cells were puriﬁed
using the mouse B cell Isolation Kit (Miltenyi Biotec, Auburn, CA, USA)
and the purity of B cells was always above 92%. For B cells culture, puri-
ﬁed B cells were cultured in phenol red-free RPMI 1640 medium
containing 10% charcoal-stripped FBS, 2 mM L-glutamine, 100 IU/mL
penicillin, 100 μg/mL streptomycin, and 1% nonessential amino acids.
2.3. Isolation of human peripheral blood mononuclear cells
Blood samples were obtained from 15 healthy menopausal women
and 10healthy age-matchedmen. Humanperipheral bloodmononucle-
ar cells (PBMCs) were separated from plasma by Ficoll centrifugation
(Lymphoprep, Nycomed, Oslo, Norway) according to the standardprocedures. The harvested PBMCs were stored in TRIZOL reagent
(Invitrogen, Carlsbad, CA, USA) at−80 °C for using.2.4. Cell viability assay
The effect of 17β-estradiol on viability ofmurine B cells was evaluat-
ed using the Cell CountingKit 8 (CCK-8) according to themanufacturer's
instructions. In brief, murine B cells were cultured in 96-well plates
(5 × 103/100 μL/well) and incubated with various concentrations of
17β-estradiol for 24 h. Subsequently, the CCK-8 solution was added to
each well (10 μL/well) and incubated for another 3 h. The absorbance
at 450 nm was measured using microplate reader (Synergy HT,
Bio-Tek).2.5. Reverse transcription PCR (RT-PCR) and quantitative real-time PCR
(qPCR) analysis
Total RNA was extracted using TRIZOL (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer's instructions. RNA concentration
was quantiﬁed by a SmartSpecTM Plus spectrophotometer (Bio-Rad,
Hercules, CA) and RNA integrity was analyzed with formaldehyde de-
naturalization agarose gel electrophoresis. The method to quantify
mRNA and miRNA was performed as described previously [57]. qPCR
assays of mRNA and mature miRNAs were carried out on a StepOne
Plus real-time polymerase chain reaction system or ABI Vii 7 detection
system (Applied Biosystems, Foster City, CA) using SYBR Green PCR
Master Mix. The 2−ΔΔCt method was used for qPCR gene expression
analysis. All quantiﬁcation data were presented as a ratio to the
GAPDH or U6 level.2.6. Western blot analysis
Proteinswere extracted using lysis buffer and the protein concentra-
tion of each samplewas detected using the BCAprotein assay kit (Pierce
Chemical, Rockford, IL). Appropriate amounts of proteins (50 μg) were
electrophoresed on SDS polyacrylamide gels with Tris-glycine running
buffer and electrically transferred onto polyvinylidene diﬂuoride mem-
branes (MilliporeCorp, Bedford, MA). After blocking with 3% (w/v)
bovine serum albumin (BSA) in Tris buffered saline (TBS)/Tween-20
(Bio-Rad Laboratories, Richmond, CA, USA) for 1 h, the membranes
were washed and then incubated with primary antibodies against
TLR7, phos-STAT1 (Ser 727), total STAT1 and IKKε which were pur-
chased from Cell Signaling Technology (Danvers, MA) (all dilution at
1:1000) over night at 4 °C. Afterwashing, themembraneswere incubat-
ed at room temperature with the secondary antibody AfﬁniPure Goat
Anti-Rabbit IgG (H+ L) purchased from Beyotime Institute of Biotech-
nology (Haimen, China) (dilution at 1:3000) for 1 h. The ECL Plus west-
ern blotting detection reagents (Millipore, USA) were used to visualize
protein expressions. The control protein GAPDH (dilution at 1:1000)
was purchased from Cell Signaling Technology (Danvers, MA). Integrat-
ed density values were then calculated using an AlphaImager 3400
(Alpha Innotech).2.7. Mouse ovariectomy and 17β-estradiol exposure
Twelve C57BL/6 mice, 4 weeks old, were surgically ovariectomized
(OVX) after anesthesia using chloral hydrate and divided into two
groups randomly. Mice were well owed to recover for two weeks and
then implanted with Alzet mini-osmotic pumps (Model 1004; Durect
Corp., Cupertino, CA, USA) delivering 0.2 μg/day 17β-estradiol or vehicle
(0.5% ethanol and 99.5% polypropyleneglicol) for 4 weeks. Implants
were placed in the subscapular region.
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For 3H-thymidine uptake, the isolated murine splenic B cells were
cultured in 96-well plate at a density of 2 × 106 cells/mL. After
pretreated with 10 nM 17β-estradiol or vehicle for 24 h, the B cells
were stimulated with TLR7 ligand R848 (1 μg/mL, Enzo Life Sciences
International), TLR9 ligand CpG-1826 (0.3 μM, Invitrogen), AfﬁniPure
F(ab′)2 FragmentGoat Anti-Mouse IgM(10 μg/mL, Jackson ImmunoResearch
Laboratories) or IFN-α (1000 U/mL, eBioscience). After cultured with their
respective stimuli for 48 h, B cells were pulse-labeled with (3H) thymidine
(0.2 μCi/well, Amersham Life Science, Little Chalfont, UK) for 6 h before har-
vest. Cells were harvested over glass ﬁber ﬁlters and radionuclide uptake
was measured by scintillation counting. All experiments were performed in
triplicate and were repeated three times.
2.9. Phenotype and intracellular protein analysis by ﬂow cytometry
For phenotype staining, cells were washed twice with phosphate
buffered saline (PBS) containing 1% FBS and 0.1% NaN3. Then cells
were incubated for 30 min at 4 °C with mouse CD45R (B220)-FITC anti-
body (Miltenyi Biotec, Auburn, CA, USA), mouse CD69-PE antibody
(eBioscience, San Diego, CA, USA) or mouse CD86-APC antibody
(eBioscience, San Diego, CA, USA) according to the standard procedure.
For intracellular staining, cells were washed twice with PBS containing
1% FBS and 0.1% NaN3. Then cells were resuspended with pulse vortex
and 100 μL IC ﬁxation buffer (eBioscience, San Diego, CA, USA) was
added. After being incubated at 4 °C for 20 min in the dark, cells were
washed twice with 2 mL permeabilization buffer (eBioscience, San
Diego, CA, USA) and centrifuged. Next, intracellular staining was per-
formed in 100 μL of permeabilization buffer by using TLR7 Ab and
IKKε Ab (dilution at 1:100, Cell Signaling Technology). After being incu-
bated for 20 min in the dark at room temperature, cells were incubated
with PE-conjugated F(ab′)2 Donkey Anti-Rabbit IgG antibody (dilution
at 1:200, Miltenyi Biotec, Auburn, CA, USA) for 20 min in the dark at
room temperature. After beingwashed twicewith 2mLpermeabilization
buffer, cells were analyzed by FACS Calibur (Becton Dickinson). An
isotype control was used for each antibody. Data analysis was performed
using the FlowJo (TreeStar, San Carlos, CA, USA).
2.10. Luciferase assay
WEHI-231 cells were co-transfected with ISRE luciferase reporter
plasmid (2 μg, Promega, Madison, WI, USA), renilla luciferase reporter
plasmids (0.2 μg, Promega, Madison, WI, USA) with small interfering
RNAagainst IKKε ormimic ofmiRNA. After 24 h, the cellswere stimulat-
edwith IFN-α for 18 h and harvested in luciferase assay lysis buffer, and
luciferase activitywasmeasured according to themanufacturer's proto-
col (Promega). Values for luciferase activity were normalized to renilla
luciferase activity. In all cases, data represent the average values of trip-
licate samples normalized to co-transfected renilla luciferase activity,
expressed as a percentage of the control stimulated sample value.
2.11. Plasmid construct and transfection
Mouse IKKε cDNA was PCR-ampliﬁed using the primer pair: FP:
5-CCACACTGGACTAGTGGATCCATGCAGAGTACCACTAACTAC-3, RP: 5-
GAGTTTTTGTTCGGGCCCAAGCTTTCAGACATCTGGTGCCGATGG-3. The
product was cloned into the BamH1/HindIIIsites of pcDNA3.1-Myc-
His (Invitrogen, Carlsbad, CA, USA), resulting in IKKε-containing
pcDNA3.1. IKKε-containing pcDNA3.1 plasmid (2 μg) was transfected
into WEHI-231 cells using the nucleofector device (Amaxa, Köln,
Germany) and mouse cell line kit R (Amaxa Biosystems, Gaithersburg,
MD). WEHI-231 cells were transfected with empty vector as matched
control. Cells were harvested and used for subsequent experiments
after 36 h or 48 h. Transfection efﬁciency, as determined by greenﬂuorescent protein expression in parallel plates, varied between 50%
and 60%.
2.12. Small interfering RNA (siRNA)
The siRNA sequences used for silencing mouse IKBKE, Esr1 and Esr2
were purchased from RIBOBIO (Guangzhou, Guangdong, China).
The sequences of siRNA as follows: For mouse IKBKE, FP: 5-GCAUAC
UGAUGACCUGCUAdTdT-3; RP: 3-dTdTCGUAUGACUACUGGACGAU-5;
for mouse Esr1, FP: 5-GCAGUAACGAGAAAGGAAAdTdT-3; RP: 3-
dTdTCGUCAUUGCUCUUUCCUUU-5; and for mouse Esr2, FP: 5-CCAA
UCAUCGCUUCUCUAUdTdT-3; RP: 3-dTdTCGUCAUUGCUCUUUCCUUU-
5. The nucleofector device (Amaxa, Köln, Germany) and mouse cell
line kit R (Amaxa Biosystems, Gaithersburg, MD)were used to transfect
siRNA duplexes into WEHI-231 cells. Cells were harvested and used for
subsequent experiments after 36 h and 48 h.
2.13. Transfection of miRNA mimics and inhibitors
Mimics (double-stranded chemically modiﬁed RNA oligonucleo-
tides) and inhibitors (single-stranded chemically enhanced oligonucle-
otides) of let-7e-5p, miR-98-5p, miR-145a-5p (GenePharma Co., Ltd.,
Shanghai, China) were used to supplement and suppress the activities
of let-7e-5p, miR-98-5p, miR-145a-5p in mouse B cell line WEHI-231
cells. The nucleofector device (Amaxa, Köln, Germany) and mouse cell
line kit R (Amaxa Biosystems, Gaithersburg, MD)were used to transfect
miRNA mimics or inhibitors to WEHI-231 cells. Negative control of
mimics and inhibitors were transfected as matched controls. Cells
were harvested and used for subsequent experiments after 36 h and
48 h.
2.14. PGL3-IKBKE-3′UTR construct and luciferase analysis
Mouse genomic DNA served as template to amplify IKBKE-3′UTR.
The ampliﬁed PCR products were gel-puriﬁed and digested with Xba I
(Takara, Otsu, Japan). They were inserted into downstream of the lucif-
erase reporter gene at the XbaI-cloning sites of the pGL3 control vector
(Promega, Madison, WI), resulting in PGL3-IKBKE-3′UTR. For luciferase
assay, 293T cells were cotransfected with the luciferase reporter con-
structs described above (0.2 μg), renilla luciferase reporter plasmids
(0.02 μg, Promega, Madison, WI, USA) and the appropriate microRNA
mimics or inhibitors using Lipofectamine™ 2000 Reagent (Life Technol-
ogies, Karlsruhe, Germany). The luciferase activity was measured using
the Dual-luciferase reporter assay kit (Promega, Madison, WI, USA) at
approximately 36 h after transfection. Fireﬂy luciferase activitywas nor-
malized to renilla luciferase activity.
2.15. Statistical analysis
All values in the graphswere given asmeans plus orminus standard
error of the mean (SEM). To assess statistical signiﬁcance, t-test and
ANOVA were performed using GraphPad Prism 5.0. A statistical signiﬁ-
cance was set at p b 0.05. All experiments were repeated at least three
times.
3. Results
3.1. The gender difference in the IFN-I-induced gene signature of B cells
depends on 17β-estradiol
Recent studies have shown the ability of TLRs to promote antibody
responses in B cells [20,58], and TLRs of B cells play critical roles in the
pathogenesis of SLE [21,22]. To clarify the relationship between TLR ex-
pression and estrogens in B cells,we isolated splenic B cells fromnormal
female mice (without considering the estrous cycle) and age-matched
male mice, and then the mRNA levels of TLRs were detected. As
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TLR7 were higher in females compared with males. Because TLR7 is
thought to be critically involved in the activation of B cells [59], we
next detected the protein level of TLR7 in B cells from female and
male mice. Expectedly, compared with age-matched male mice, female
mice showed a higher protein level of TLR7 (Fig. 1B).
Earlier work has noted that females show a higher level of ERα in B
cells compared with age-matched males [37]. Consistently, we also
found that females show a higher level of ERα in B cells compared
with age-matched males (Fig. 1C). Since TLR1, TLR2, TLR3 and TLR7
are IFN-I-inducible genes [60–63] and the IFN-I receptors control the
TLR expression levels in B cells [64], we next detected the expression
of IFN-I inducible genes in splenic B cells from female andmalemice. In-
terestingly,many IFN-I-induced geneswere up-regulated in B cells from
female mice compared with age-matched male mice (Fig. 1C). More-
over, the protein level of STAT1, a key IFN-I-inducible gene, was also
up-regulated in B cells from female mice (Fig. S1).Fig. 1. 17β-Estradiol contributes to the gender differences in the expression of TLRs and IFN-I-
mice (n = 8) and age-matchedmale mice (n = 8). qPCR analysis of TLR expression (A), weste
expressions (C). The data shown represent themeans of three independent experiments, and th
ns denotes p N 0.05. (D–F) Ovariotomywas performed on four-week-old femalemice. TheseOV
or 17β-estradiol (n = 6). Four weeks later, splenic B cells were isolated from these mice. qPCR
expression in peripheral blood B cells and splenic B cells (E). qPCR analysis of the expression
**p b 0.01, ***p b 0.001, as determined by ANOVA (A, C, D and F), except for FACS analysis of TTo study whether the fundamental gender difference in the IFN-I-
induced gene signature is related to estrogens, we next detected the ex-
pression of IFN-I-inducible genes in ovariectomized mice treated with
17β-estradiol or placebo. Four-week-old female C57BL/6 mice were
ovariectomized and treated with 17β-estradiol or placebo. Four weeks
later, the splenic B cells were isolated from these mice and the TLR ex-
pression levels were detected by qPCR. Intriguingly, compared with
placebo-treated mice, 17β-estradiol-treated mice showed higher ex-
pression levels of TLR1, TLR3, TLR4 and TLR7 in B cells (Fig. 1D). The pro-
tein level of TLR7 was also higher in both peripheral blood B cells and
splenic B cells from 17β-estradiol-treated mice compared with
placebo-treatedmice (Fig. 1E). 17β-Estradiol-treated mice also showed
a higher level of ERα in B cells compared with placebo-treated mice
(Fig. 1F). Moreover, the IFN-I-induced gene signature was up-
regulated in B cells from 17β-estradiol-treated mice compared with
those from placebo-treated mice (Fig. 1F). All of these results indicate
that IFN-I signaling is more activated in B cells from female miceinducible genes in B cells. (A–C) Splenic B cells were isolated from eight-week-old female
rn blot analysis of TLR7 expression (B) and qPCR analysis of ERα and IFN-I-inducible gene
e error bars represent the s.e.m. *p b 0.05, **p b 0.01, ***p b 0.001, as determined byANOVA;
Xmicewere allowed to recover for twoweeks andwere then treatedwith placebo (n=6)
analysis of TLR expression levels in splenic B cells (D). Intracellular FACS analysis of TLR7
of IFN-I-inducible gene in splenic B cells (F). The error bars represent the s.e.m. *p b 0.05,
LR7 expression (B and E) which was performed by t-test; ns denotes p N 0.05.
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der difference is related to 17β-estradiol.
3.2. 17β-Estradiol ampliﬁes the activation of IFN-α signaling in B cells
Since 17β-estradiol contributes to the gender differences in the ex-
pression of IFN-I-inducible genes in vivo, we next investigated the effectFig. 2. 17β-Estradiol ampliﬁes the activation of IFN-α signaling in B cells. (A) CCK8 analysis of t
primary B cells used in this study were all isolated from female mice). (B) qPCR analysis of TLR
(C)Western blot analysis of TLR7 expression in B cells stimulatedwith different concentrations o
to stimulationwith IFN-α (500 U/mL, eBioscience, San Diego, CA, USA). The expression levels of
protein levels of TLR7 and STAT1were analyzed bywestern blot at 24 h (E). The protein levels o
were treatedwith 10nM17β-estradiol for 24 h prior to stimulationwith R848 (1 μg/mL), CpG18
of B cells at 48 h (G). FACS analysis of the expression of CD86 (H) and CD69 (I) at 24 h. qPCR an
three independent experiments, and the error bars represent the s.e.m. *p b 0.05, **p b 0.01, **of 17β-estradiol on the activation of IFN-α signaling in B cells. B cells
isolated from female mice were treated with different concentrations
of 17β-estradiol for 24 h, and their viability was detected by CCK8
assay. As shown in Fig. 2A, 17β-estradiol had no effect on the viability
of murine B cells under the concentration of 100 nM. We next investi-
gated the effect of 17β-estradiol on the expression of IFN-I-inducible
genes. Although 17β-estradiol could enhance the mRNA and proteinhe vitality of B cells stimulated with different concentrations of 17β-estradiol for 24 h (the
7 expression in B cells stimulated with different concentrations of 17β-estradiol for 12 h.
f 17β-estradiol for 24 h. (D–F) B cells were treatedwith 10 nM17β-estradiol for 24 h prior
IFN-I-inducible genes TLR7, IFIT2, STAT1 and STAT2were analyzed by qPCR at 8 h (D). The
f p-STAT1 (Ser 727) and total-STAT1were analyzed bywestern blot at 1 h (F). (G–J) B cells
26 (0.3 μM), anti-IgM (10 μg/mL) or IFN-α (500U/mL). 3H-TdR analysis of the proliferation
alysis of the expression of IL-10 and IL-6 at 6 h (J). The data shown represent themeans of
*p b 0.001, as determined by ANOVA (A–J); ns denotes p N 0.05.
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STAT1, STAT2 and IFIT2, which are IFN-I-inducible genes (data not
shown). These results indicate that 17β-estradiol alone has no effect
on the expression of IFN-I-inducible genes in B cells.
To explore whether 17β-estradiol can amplify the activation of IFN-
α signaling in B cells, murine B cells were treated with 17β-estradiol or
vehicle for 24 h prior to stimulationwith IFN-α. As shown in Fig. 2D, the
expression of TLR7, IFIT2, STAT1 and STAT2 was higher in B cells
pretreated with 17β-estradiol compared with non-17β-estradiol-
pretreated cells. Elevated protein levels of TLR7 and STAT1 were also
observed in B cells pretreated with 17β-estradiol (Fig. 2E). Moreover,
compared with non-17β-estradiol-treated cells, B cells pretreated
with 17β-estradiol showed a higher phosphorylation level of STAT1
after stimulation with IFN-α for 1 h (Fig. 2F). What's more, 17β-
estradiol could promote IFN-α-induced expression of CD69 and TNF-α
in B cells (Fig. S2). These data suggest that 17β-estradiol can amplify
the activation of IFN-α signaling in B cells.
As many studies have suggested that IFN-α can enhance TLR- and
BCR-induced B cell activation [34,65], we next investigated whether
17β-estradiol can amplify the function of IFN-α on TLR- and BCR-
induced B cell activation. Murine B cells were treated with 17β-
estradiol or vehicle for 24 h prior to stimulation with IFN-α combined
with the TLR7 ligand R848, the TLR9 ligand CpG-1826 or anti-IgM. The
proliferation of B cells was detected at 48 h by the 3H-TdR incorporation
assay, and the expression of CD86 and CD69 was detected by FACS at
24 h. As shown in Fig. 2G, 17β-estradiol could not only promote the
IFN-α-induced proliferation of B cells but also enhance the effect of
IFN-α on amplifying the TLR-induced proliferation of B cells. Moreover,
17β-estradiol could enhance the effects of IFN-α on amplifying TLR- and
BCR-induced CD86 and CD69 expression (Figs. 2H, I and S3). What's
more, the expression of IL-6 and IL-10 induced by IFN-α, R848, CpG-
1826 and anti-IgMwas also detected. As shown in Fig. 2J, TLR7, although
TLR9 and BCR signaling could induce expression of the IL-6 and IL-10,
and IFN-α has no effect on expression of the IL-6 and IL-10, IFN-α
could signiﬁcantly promote TLRs- and BCR-induced expression of the
IL-6 and IL-10. Intriguingly, E2 treatment could signiﬁcantly enhance
the effect of IFN-α on TLR- and BCR-induced expression of the IL-6
and IL-10. Together, these results illustrate that 17β-estradiol can signif-
icantly amplify the activation of IFN-α signaling in B cells.
3.3. IKKε is necessary for 17β-estradiol-ampliﬁed activation of IFN-α
signaling
To investigate the mechanism through which 17β-estradiol am-
pliﬁes the activation of IFN-α signaling, we focused on IKKε which
plays a critical role in the activation of IFN-I signaling [41]. First, we
detected the effect of 17β-estradiol on regulating IKKε expression in B
cells. As shown in Fig. 3A, 17β-estradiol was able to up-regulate the
mRNA level of IKKε in B cells at both 12 h and 24 h. Moreover, 17β-
estradiol up-regulated the mRNA and protein levels of IKKε in a dose-
dependent manner (Fig. 3B and C).
To determine the effect of IKKε on regulating the activation of IFN-α
signaling in B cells, we transfected the IKBKE-containing pcDNA3.1
plasmid or control plasmid into WEHI-231 cells, a mouse B cell line.
As shown in Figs. S4A and S4B, both the mRNA and protein levels of
IKKε were signiﬁcantly elevated in the cells transfected with IKBKE-
containing pcDNA3.1 plasmid comparedwith the control cells. Interest-
ingly, over-expression of IKKε promoted the expression of IFN-α-
inducible genes in WEHI-231 cells without any stimulation (Fig. S4C).
We hypothesize that the reason for this ﬁnding may be that IFN-α sig-
naling in WEHI-231 cells is activated at the basic level and that STAT1
has been phosphorylated to a certain degree. Expectedly, over-
expression of IKKε signiﬁcantly promoted IFN-α-induced expression
of TLR7, STAT1, STAT2 and IFIT2 (Fig. 3D and E). Moreover, over-
expression of IKKε resulted in a higher phosphorylation level of STAT1
induced by IFN-α (Fig. 3F). To further conﬁrm this phenomenon,IFN-α-responsive luciferase reporter gene assays were conducted. As
shown in Fig. 3G, IFN-α treatment resulted in induction of ISRE-
luciferase reporter gene activity, reﬂecting the actions of the endoge-
nous ISGF3 transcription complex. IFN-α-induced ISRE-luciferase
reporter gene activity was higher in the IKKε-overexpressed WEHI-
231 cells compared with control cells. In contrast, we reduced IKKε ex-
pression in WEHI-231 cells using small interference RNA against IKKε
(Figs. S5A and S5B) and then stimulated the cells with IFN-α. IKKε
knockdown signiﬁcantly inhibited the expression of IFN-α-inducible
genes (Fig. 3H and I). Moreover, IKKε knockdown resulted in a lower
phosphorylation level of STAT1 induced by IFN-α (Fig. 3J). To further
conﬁrm the observed phenomenon, IFN-α-responsive luciferase report-
er gene assays were also conducted. Compared with control cells, IKKε
knockdown signiﬁcantly reduced IFN-α-induced ISRE-luciferase report-
er gene activity (Fig. 3K). All of these data demonstrate that IKKε indeed
promotes the activation of IFN-α signaling in B cells.
To further assesswhether IKKε is necessary for 17β-estradiol to pro-
mote the activation of IFN-α signaling in B cells, WEHI-231 cells were
transfected with siRNA against IKKε or control for 24 h prior to stimula-
tionwith 17β-estradiol for 24 h, and then the cellswere stimulatedwith
IFN-α. As shown in Fig. 3L, 17β-estradiol could increase the IFN-α-
induced phosphorylation of STAT1 in control cells, whereas it had no ef-
fect in the IKKε-lowexpressed cells. Moreover, WEHI-231 cells were
transfected with ISRE luciferase reporter plasmid and siRNA against
IKKε for 24 h prior to stimulation with 17β-estradiol for 24 h, and
then the cells were stimulated with IFN-α for 18 h. The luciferase
assay showed that 17β-estradiol could increase IFN-α-induced ISRE-
luciferase reporter gene activity in control cells, whereas it had no effect
in IKKε-lowexpressed cells (Fig. 3M). These data showed that IKKε is
necessary for 17β-estradiol to promote the activation of IFN-α signaling
in B cells.
3.4. 17β-Estradiol promotes IKKε expression by down-regulating the
expression of let-7e-5p, miR-98-5p and miR-145a-5p
To investigate how 17β-estradiol up-regulates IKKε expression, we
focused on estrogen-regulated miRNAs. We ﬁrst selected several
miRNAs down-regulated by 17β-estradiol, including let-7e-5p, miR-
16-5p, miR-98-5p, miR-143-3p, miR-145a-5p and miR-195a-5p,
which were predicted to target the 3′UTR of IKBKE (synthetic gene of
IKKε) as previously described [48,54,55].MurineB cellswere stimulated
with 17β-estradiol or vehicle for 6 h and then the expression of these
miRNAs was detected. As shown in Fig. 4A, 17β-estradiol could signiﬁ-
cantly down-regulate the expression of let-7e-5p, miR-98-5p and
miR-145a-5p. To investigate whether the three miRNAs could target
the 3′UTR of IKBKE directly, the luciferase reporter system was used to
validate the target site. IKBKE-3′UTR, which contains putative binding
site of let-7e-5p, miR-98-5p and miR-145a-5p, was subcloned down-
stream of the f-luc open reading frame in the PGL3 vector. The reporter
constructwas co-transfected in theHEK293T cell linewith pRL-CMV (to
normalize for transfection differences) and either mimics or inhibitors
of the miRNAs. Compared with the negative control, over-expression
of the three miRNAs could signiﬁcantly reduce the luciferase activities,
whereas inhibiting the expression of the three miRNAs signiﬁcantly in-
creased the luciferase activities (Fig. 4B). These data indicate that let-7e-
5p, miR-98-5p and miR-145a-5p can all interfere with mRNA transla-
tion via direct interaction with the 3′UTR of IKBKE. To examine the
effects of these miRNAs on IKKε expression, mimics or inhibitors of
let-7e-5p, miR-98-5p or miR-145a-5p were transfected into WEHI-
231 cells for 36 h (Fig. S6), and then the expression of IKKεwas detect-
ed. Over-expression of let-7e-5p, miR-98-5p or miR-145a-5p signiﬁ-
cantly reduced the mRNA level of IKKε, whereas inhibiting the
expression of three miRNAs enhanced the mRNA level of IKKε
(Fig. 4C). Consistently, over-expression of the three miRNAs could
reduce the protein level of IKKε, whereas inhibiting the expression of
the three miRNAs enhanced the protein level of IKKε (Fig. 4D–H).
Fig. 3. 17β-Estradiol ampliﬁes the activation of IFN-α signaling via IKKε. (A) qPCR analysis of IKKε expression in murine splenic B cells stimulated with 10 nM 17β-estradiol for different
times. (B) qPCR analysis of IKKε expression in murine splenic B cells stimulated with different concentrations of 17β-estradiol for 12 h. (C) Western blot analysis of IKKε expression in
murine splenic B cells stimulated with different concentrations of 17β-estradiol for 24 h. (D–F) WEHI-231 cells (a mouse B cell line) were transfected with pcDNA3.1-IKKε plasmid or
control for 36 h and subsequently stimulatedwith IFN-α (500 U/mL). The expression of IFN-I inducible genes TLR7, STAT1 and IFIT2was analyzed by qPCR at 8 h (D). The expression levels
of TLR7 and STAT1were analyzed bywestern blot at 24 h (E). The phosphorylation level of STAT1was analyzed bywestern blot at 1 h (F). (G) Luciferase reporter analysis of the luciferase
activity inWEHI-231 cells stimulatedwith IFN-α for 18 h. (H–J)WEHI-231 cells were transfectedwith Si-NC or Si-IKKε for 36 h and subsequently stimulatedwith IFN-α (500 U/mL). The
expression of IFN-I inducible genes STAT1, STAT2, IFIT2 and TLR7 was analyzed by qPCR at 8 h (H). The expression of TLR7 and STAT1 was analyzed by western blot at 24 h (I). The phos-
phorylation level of STAT1 was analyzed by western blot at 1 h (J). (K) Luciferase reporter analysis of the luciferase activity in WEHI-231 cells after stimulation with IFN-α for 18 h.
(L) WEHI-231 cells were transfected with Si-NC or Si-IKKε for 24 h, treated with 17β-estradiol for 24 h and stimulated with IFN-α (500 U/mL). The phosphorylation level of STAT1
was analyzed by western blot at 1 h. (M) Luciferase reporter assay of the luciferase activity in WEHI-231 cells stimulated with IFN-α for 18 h. The data shown represent the means of
three independent experiments, and the error bars represent the s.e.m. *p b 0.05, **p b 0.01, ***p b 0.001, as determined by ANOVA (A–M); ns denotes p N 0.05.
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expression, we next investigated the effects of let-7e-5p, miR-98-5p
and miR-145a-5p on IFN-α signaling activation. WEHI-231 cells were
transfected with mimics or inhibitors of the three miRNAs for 36 h
prior to stimulation with IFN-α. As shown in Fig. 4I, over-expression
of let-7e-5p, miR-98-5p and miR-145a-5p inhibited IFN-α-induced
expression of TLR7 and STAT1, whereas inhibiting the expression of
let-7e-5p, miR-98-5p and miR-145a-5p promoted IFN-α-induced ex-
pression of TLR7 and STAT1 (Fig. 4J). Consistently, over-expression of
the three miRNAs also reduced the phosphorylation of STAT1 induced
by IFN-α, whereas inhibiting the expression of the three miRNAs en-
hanced the phosphorylation of STAT1 induced by IFN-α (Fig. 4K and L).
To investigate whether the three miRNAs are essential for 17β-
estradiol to regulate the activation of IFN-α signaling in B cells, we neu-
tralized 17β-estradiol-induced down-regulation of let-7e-5p, miR-98-
5p and miR-145a-5p by transfecting mimics of let-7e-5p, miR-98-5p
and miR-145a-5p in WEHI-231 cells. WEHI-231 cells were transfected
with different concentrations of mimics of let-7e-5p, miR-98-5p or
miR-145a-5p for 24 h prior to treatment with 17β-estradiol for 6 h. Asshown in Fig. S7, 17β-estradiol could down-regulate the expression of
let-7e-5p, miR-98-5p andmiR-145a-5p signiﬁcantly in negative control
cells. However, the expression of let-7e-5p,miR-98-5p andmiR-145a-5p
in 17β-estradiol-treated cells was completely reversed by transfection
with mimics of let-7e-5p (4 nM), miR-98-5p (6 nM) and miR-145a-5p
(4 nM), and was similar to the levels in non-treated cells. To investigate
whether transfection of mimics of let-7e-5p (4 nM), miR-98-5p (6 nM)
or miR-145a-5p (4 nM) can reverse the effect of 17β-estradiol on regu-
lating the activation of IFN-α signaling, WEHI-231 cells were transfected
with mimics of let-7e-5p (4 nM), miR-98-5p (6 nM) or miR-145a-5p
(4 nM) for 24 h prior to treatment with 17β-estradiol for 24 h and
then the cells were stimulated with IFN-α. As shown in Fig. 4M and N,
transfection with mimic of let-7e-5p, miR-98-5p or miR-145a-5p alone
could partially reverse 17β-estradiol-dependent enhancement of IFN-
α-induced TLR7 and STAT1 expression and phosphorylation of STAT1.
Moreover, transfection of mimic let-7e-5p, miR-98-5p and miR-145a-
5p together could completely reverse 17β-estradiol-dependent
enhancement of IFN-α-induced TLR7 and STAT1 expression, and phos-
phorylation of STAT1. Furthermore, IFN-α-responsive luciferase reporter
Fig. 4. 17β-Estradiol promoted IKKε expression and IFN-α signaling activation by down-regulating the expression of let-7e-5p, miR-98-5p and miR-145a-5p. (A) qPCR analysis of
microRNA expression in murine B cells stimulated with 10 nM 17β-estradiol for 6 h. (B) Luciferase reporter analysis of the binding abilities of let-7e-5p, miR-98-5p and miR-145a-5p
to the 3′-UTR of IKBKE. (C–F) WEHI-231 cells were transfected with mimics or inhibitors of let-7e-5p, miR-98-5p and miR-145a-5p for 36 h and 48 h. qPCR analysis of IKKε expression
at 36 h (C). Western blot analysis of IKKε expression in WEHI-231 cells transfected with mimics and inhibitors of let-7e-5p (D), miR-98-5p (E) and miR-145a-5p (F). (G–H) Statistical
analysis of the protein levels of IKKε shown in panels D–F. (I–K) WEHI-231 cells were transfected with mimics (100 nM) or inhibitors (100 nM) of let-7e-5p, miR-98-5p or miR-145a-
5p for 36 h prior to stimulation with IFN-α (500 U/mL). qPCR analysis of TLR7 and STAT1 expression levels at 8 h (I, J). Western blot analysis of the phosphorylation of STAT1 at 1 h
(K, L). (M, N) WEHI-231 cells were transfected with mimics of let-7e-5p (4 nM), miR-98-5p (6 nM) or miR-145a-5p (4 nM) for 24 h prior to treatment with 17β-estradiol for 24 h
and then the cells were stimulated with IFN-α (500 U/mL). qPCR analysis of TLR7 and STAT1 expression levels at 8 h (M). Western blot analysis of the phosphorylation level of
STAT1 at 1 h (N). (O) Luciferase reporter analysis of the luciferase activity induced by IFN-α in WEHI-231 cells transfected with mimics let-7e-5p (4 nM), miR-98-5p (6 nM) or miR-
145a-5p (4 nM). The data shown represent the means of three independent experiments, and the error bars represent the s.e.m. *p b 0.05, **p b 0.01, as determined by ANOVA (A–O);
ns denotes p N 0.05.
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the ISRE luciferase reporter plasmid with mimics of let-7e-5p (4 nM),
miR-98-5p (6 nM) or miR-145a-5p (4 nM) for 24 h prior to treatment
with 17β-estradiol for 24 h, and then the cells were stimulated with
IFN-α. As shown in Fig. 4O, 17β-estradiol increased IFN-α-induced
ISRE-luciferase reporter gene activity in control cells, while transfection
with mimics of let-7e-5p, miR-98-5p or miR-145a-5p alone could par-
tially inhibit the effect of 17β-estradiol on promoting IFN-α-induced
ISRE-luciferase reporter gene activity. Notably, transfection with mimics
of let-7e-5p, miR-98-5p and miR-145a-5p together could completely
inhibit the effect of 17β-estradiol on promoting IFN-α-induced ISRE-
luciferase reporter gene activity. These results demonstrate that17β-estradiol promotes the activation of IFN-α signaling in B cells, at
least in large part, by down-regulating the expression of let-7e-5p,
miR-98-5p and miR-145a-5p.3.5. 17β-Estradiol down-regulates let-7e-5p, miR-98-5p and miR-145a-5p
expressions via estrogen receptor α
To investigate whether estrogen receptor α (ERα) or β (ERβ) medi-
ates the effect of 17β-estradiol on down-regulating the expression of let-
7e-5p, miR-98-5p and miR-145a-5p, murine B cells were treated with
the ER inhibitors tamoxifen and IcI 182,780 for 6 h prior to stimulation
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miR-145a-5p was examined. Intriguingly, tamoxifen and IcI 182,780 re-
versed 17β-estradiol-induced down-regulation of let-7e-5p, miR-98-5p
andmiR-145a-5p (Fig. 5A), indicating that 17β-estradiol exerts its func-
tion via ER. Then murine B cells were stimulated with the ERα agonist
PPT or the ERβ agonist DPN for 6 h, and the expression of let-7e-5p,
miR-98-5p and miR-145a-5p was detected. As shown in Fig. 5B, PPT
could down-regulate the expression of let-7e-5p, miR-98-5p and miR-
145a-5p to the similar levels in 17β-estradiol-stimulated cells, whereas
DPN had no effect. Moreover, PPT could up-regulate both the mRNAFig. 5.17β-Estradiol down-regulates let-7e-5p,miR-98-5p andmiR-145a-5pexpression via estr
for 6 h prior to stimulationwith 10 nM17β-estradiol for 6 h. qPCR analysis of the expression of
17β-estradiol, 10 nM PPT or 10 nM DPN. qPCR analysis of the expression of let-7e-5p, miR-98-
analysis of IKKε expression at 24 h (D). (E, F)WEHI-231 cells were transfectedwith siRNA again
(E). Western blot analysis of the expression of ERα and ERβ at 48 h (F). (G) WEHI-231 cells w
estradiol for 6 h. qPCR analysis of the expression of let-7e-5p, miR-98-5p, and miR-145a-5p.
bars represent the s.e.m. *p b 0.05, **p b 0.01, ***p b 0.01, as determined by ANOVA (A–G); nsand protein levels of IKKε, whereas DPN had no effect (Fig. 5C and D).
These results suggest that 17β-estradiol down-regulates the expression
of let-7e-5p,miR-98-5p andmiR-145a-5p and enhances IKKε expression
via ERα.
To conﬁrm the above-presented results, ERα and ERβ interference
assays were conducted. As shown in Fig. 5E and F, expression of ERα
and ERβ was down-regulated in WEHI-231 cells transfected with
siRNA against ERα or ERβ. Interestingly, ERα knockdown reversed
17β-estradiol-induced down-expression of let-7e-5p, miR-98-5p and
miR-145a-5p, whereas ERβ knockdown had no effect (Fig. 5G). Theseogen receptorα. (A)Murine B cellswere treatedwith 1 μMtamoxifen (TAM) or ICI 182,780
let-7e-5p, miR-98-5p andmiR-145a-5p. (B–D)Murine B cells were stimulatedwith 10 nM
5p and miR-145a-5p at 6 h (B). qPCR analysis of IKKε expression at 16 h (C). Western blot
st ERα (100 nM) or ERβ (100 nM). qPCR analysis of the expression of ERα and ERβ at 36 h
ere transfected with siRNA against ERα or ERβ for 48 h and then stimulated with 17β-
The data shown represent the means of three independent experiments, and the error
denotes p N 0.05.
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5p, miR-98-5p and miR-145a-5p were dependent on ERα.3.6. 17β-Estradiol contributes to the gender differences in expression of
IKKε, let-7e-5p, miR-98-5p and miR-145a-5p in vivo
To investigate whether 17β-estradiol can regulate the expression of
IKKε, let-7e-5p, miR-98-5p and miR-145a-5p in vivo, we ﬁrst detected
the expression of IKKε in B cells from female and age-matched male
mice. As shown in Fig. 6A and B, both the mRNA and protein levels of
IKKε were higher in female mice compared with age-matched male
mice. Moreover, compared with placebo-treated OVX mice, 17β-
estradiol-treated OVX mice showed a higher mRNA level of IKKε in
splenic B cells (Fig. 6C). Increased protein expression of IKKε was also
observed in B cells from the spleen and peripheral blood of 17β-
estradiol-treated OVX mice (Fig. 6D and E).
What's more, the expression of let-7e-5p, miR-98-5p and miR-14a-
5p in female and male mice was detected. Compared with age-
matched male mice, female mice showed lower levels of let-7e-5p,
miR-98-5p and miR-14a-5p in splenic B cells (Fig. 6F). Lower levels of
let-7e-5p, miR-98-5p and miR-145a-5p were also observed in splenic
B cells from 17β-estradiol-treated OVX mice compared with placebo-
treated OVX mice (Fig. 6G). These data indicate that 17β-estradiol
indeed contributes to the gender differences in expression of IKKε,
let-7e-5p, miR-98-5p and miR-145a-5p observed in B cells in vivo.Fig. 6.Genderdifferences in expression of IKKε, let-7e-5p,miR-98-5pandmiR-145a-5p in vivo. q
femalemice (n= 8) and age-matchedmalemice (n= 8). qPCR (C) and intracellular FACS (D)
and placebo-treated OVXmice (n= 6). (E) Intracellular FACS analysis of IKKε expression in per
(F) qPCR analysis of the expression of let-7e-5p, miR-98-5p andmiR-145a-5p in splenic B cells f
ysis of the expression of let-7e-5p, miR-98-5p and miR-145a-5p in splenic B cells from 17β-est
represent themeans of three independent experiments, and the error bars represent the s.e.m.
sion levels of let-7e-5p, miR-98-5p and miR-145a-5p (F and G) which was performed by ANO3.7. Gender difference in the IFN-I-induced gene signature in human PBMCs
To determine whether the gender difference in IFN-I-induced gene
signature exists in humans, we analyzed the expression of IFN-I-
inducible genes in PBMCs from healthy pre-menopausal women and
age-matched men. Consistently with the observed phenomena in
mice, an up-regulated IFN-I-induced gene signature was observed in
PBMCs from healthy pre-menopausal women compared with age-
matched men (Fig. 7A). Moreover, we examined the expression of
IKKε, let-7e-5p, miR-98-5p and miR-145a-5p in PBMCs from women
and men. As shown in Fig. 7B, the expression of IKKε was higher in
PBMCs from women compared with men, and the expression levels of
let-7e-5p, miR-98-5p and miR-145a-5p were lower in the PBMCs from
women compared with men (Fig. 7C). These data again displayed the
gender difference in the IFN-I-induced gene signature in B cells, sug-
gesting that a similar mechanism of estrogen action may exist in both
human and mice.
3.8. Proposed regulatory pathway through which 17β-estradiol ampliﬁes
the activation of IFN-α signaling in B cells
The proposed regulatory pathway throughwhich 17β-estradiol am-
pliﬁes the activation of IFN-α signaling in B cells is shown in Fig. 8. 17β-
Estradiol down-regulates the expression of let-7e-5p, miR-98-5p and
miR-145a-5p via ERα, and subsequently enhances IKKε expression.
IKKε promotes the activation of IFN-α signaling by phosphorylatingPCR (A) andwestern blot (B) analysis of IKKε expression in splenic B cells from8-week-old
analysis of IKKε expression in splenic B cells from 17β-estradiol-treated OVXmice (n= 6)
ipheral blood B cells from 17β-estradiol-treated OVXmice and placebo-treated OVXmice.
rom 8-week-old femalemice (n=8) and age-matchedmalemice (n=8). (G) qPCR anal-
radiol-treated OVX mice (n= 6) and placebo-treated OVX mice (n= 6). The data shown
*p b 0.05, **p b 0.01, as determined by t-test (A–E), except for qPCR analysis of the expres-
VA.
Fig. 7. Gender differences in expression of IFN-I-inducible genes, IKKε, let-7e-5p, miR-98-5p and miR-145a-5p in human PBMCs. (A–C) qPCR analysis of the expression levels of IFN-I-in-
ducible genes (A), IKKε (B), let-7e-5p,miR-98-5p andmiR-145a-5p (C) in PBMCs fromhealthypre-menopausalwomen (n=15) andage-matchedmen (n=10). The error bars represent
the s.e.m. *p b 0.05, **p b 0.01, ***p b 0.01, as determined by one-way ANOVA (A and C), except for qPCR analysis of the expression of IKKε (B) which was performed by t-test.
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standing themechanism underlying the gender difference in the preva-
lence of SLE.4. Discussion
Females are more susceptible to SLE compared with males, and es-
trogens play a critical role in the pathogenesis of SLE [1,4]. In the present
study, we found that females displayed an up-regulated IFN-I-induced
gene signature in B cells compared with age-matched males and the
gender difference was related to 17β-estradiol. Importantly, 17β-
estradiol could amplify the activation of IFN-α signaling in B cells via
IKKε by down-regulating the expression of let-7e-5p, miR-98-5p and
miR-145a-5p.Fig. 8. Proposed effective mechanism of 17β-estradiol oAs iswell known, B cells play a central role in the pathogenesis of SLE
[14,17]. TLRs, particularly TLR7 and TLR9, of B cells have been identiﬁed
as possible key players in the autoimmune pathophysiology based on
their contribution to the immunological response to well-known self-
antigens, such as single-stranded RNA (ssRNA) and DNA, respectively
[19,20]. Previous studies have shown that estrogens contribute to the
sex-based difference in expression of TLRs in peritoneal leukocytes of
mice and rats, including TLR2, TLR3 and TLR4 [22]. However, it is still
unknown whether estrogens can regulate the TLR expression of B
cells. In this study, we found that female mice expressed higher levels
of TLR1, TLR3, TLR4, TLR5 and TLR7 in B cells compared with age-
matched male mice. As several TLRs, including TLR1, TLR2, TLR3, TLR5
and TLR7, are IFN-I-inducible genes [60–63], we then found that the
gender difference in TLR expression of B cells was related to the activa-
tion of IFN-I signaling.n amplifying IFN-α signaling activation in B cells.
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in B cells by up-regulating the expression of IKKε, which can phosphor-
ylate STAT1 and increase the pool of STAT1 available to associate with
STAT2 and IRF9 to optimally assemble the critical IFN-I transcription
factor complex ISGF3. This observation is consistent with a previous re-
port that 17β-estradiol can enhance the ability of STAT1 to bind to ISRE
[66]. Multiple studies have reported that IKKε phosphorylates speciﬁc
serine residues in the transcription factors IRF3 and IRF7 in response
to virus infection [67,68] and promotes formation of the IFN-β
enhanceosome [69]. Interestingly, the severity and incidence of innate
immune conditions, such as sepsis and post-surgery infections, are pro-
foundly less in women compared with age-matchedmen [70,71]. Thus,
we propose that estrogenmay participate in the sex-based difference in
the pathogenesis of infectious diseases through IKKε.
miRNAs are involved in the effect of estrogens on regulating the im-
mune response and inﬂammatory processes [48,49]. Dysregulation of
miRNAs has been reported in autoimmune diseases, including SLE [50,
51]. In particular, estrogen-regulated miRNAs modulate both innate
and adaptive immune responses [48,49]. In the present study, we
identiﬁed three miRNAs down-regulated by 17β-estradiol, including
let-7e-5p, miR-98-5p andmiR-145a-5p. Let-7e-5p can promote the de-
velopment of Th1 and Th17 cells, and the inhibition of let-7e-5p shifts
the immune response to a Th2 proﬁle and attenuates the severity of ex-
perimental autoimmune encephalomyelitis [72]. MiR-98-5p negatively
regulates IL-10 production and endotoxin tolerance in macrophages
after LPS stimulation [73]. Moreover, miR-98-5p regulates fas expres-
sion and the sensitivity of fas-mediated apoptosis [74]. The expression
of miR-145a-5p is altered in T cells from patients with SLE and subse-
quently affects the expression of its target proteins STAT-1 [75]. These
ﬁndings suggest that let-7e-5p, miR-98-5p and miR-145a-5p indeed
play roles in the pathogenesis of SLE.
In this study, we found that the inhibition of miR-145a-5p increased
the IKKε transcript level signiﬁcantly, but the resulting increase in the
protein level of IKKε was not remarkable. As is known, a signal miRNA
can potentially regulate the expression of multiple genes and their
encoded proteins [76]. miRNAs were initially thought to repress their
target proteins with little or no impact on their mRNA levels [77]. How-
ever, many studies have recently indicated that mammalian miRNAs
may predominantly act by decreasing the target mRNA levels [78].
Although most studies have focused on the ability of miRNAs to silence
genes, some recent data also suggest that some miRNAs may also in-
crease protein translation under certain conditions [79]. We hypothe-
size that miR-145a-5p may target other proteins involved in the
protein synthesis of IKKε and thereby inﬂuence theprotein level of IKKε.
In our study, manipulation of microRNAs alone impacts readouts
used to measure IFN-α-induced activation. As is known, the WEHI-
231 cells aremouse B-lymphoma cell line and the JAK1-STAT1 signaling
was slightly activated at basal level. As shown in Fig. 4, the effects of
microRNAs on the readouts used to measure IFN-α-induced activation
are very slight compared with the effect of IFN-α on the readouts and
can be negligent. We have shown that let-7e-5p, miR-98-5p and miR-
145a-5p could regulate IKKε expression by targeting the 3′UTR of IKKε
(Fig. 4B–F) and IKKε could promote IFN-α-induced activation of JAK1-
STAT1 signaling (Fig. 3D–K). Thus, it's reasonable that manipulation of
microRNAs could impact IFN-α-induced activation of JAK1-STAT1
signaling (e.g. Fig. 4K and L).
Estrogens can modulate the function of immune cells through the
transcriptional activity of nuclear ERα and ERβ [80]. Recent studies re-
vealed that ERα, rather than ERβ, plays a critical role in regulating the
estrogen-mediated promotion of inﬂammatory responses [81], autoim-
munity in NZB/WF1 mice [82] and miRNA induction in the MCF-7 cell
line [83]. Importantly, the expression of functional membrane-
associated ERα in different cell types, including lymphocytes, was re-
cently reported [84,85], and an autoantibody speciﬁc to ERα has been
detected in sera from patients with SLE [86]. Consistent with previous
studies, our study showed that 17β-estradiol down-regulated theexpression of let-7e-5p, miR-98-5p and miR-145a-5p via ERα rather
than ERβ in B cells. Unsatisfactorily, the transfection efﬁciency was not
very high (50%–60%), leading to the knockdown of ERα was not very
efﬁcient. Thus, 17β-estradiol may bind to the residual ERα and subse-
quently activate the downstream signaling pathways to a certain extent
after stimulation with 17β-estradiol. Therefore, 17β-estradiol can still
down-regulate the expression levels of these miRNAs in WEHI-231
cells transfected with siRNA against ERα.
In our study, the dosage of 17β-estradiol used was 10 nM, which is
10-fold higher than the physiological level found in mice [87]. In fact,
in some of our experiments, a 17β-estradiol dosage of 1 nM was used
(Figs. 2 and 3), and its effect is displayed. It is certain that 17β-
estradiol exerts a stronger effect at 10 nM than at 1 nM. We also
found that the 17β-estradiol dosage of at 10 nM has been used in
many studies [88,89].We thus chose 10 nM as the 17β-estradiol dosage
to show the obvious effect of 17β-estradiol on promoting the activation
of IFN-α signaling. In future studies, we must fully consider the physio-
logical level of 17β-estradiol.
SLE is a potentially fatal autoimmune disease characterized by
production of auto-antibodies targeting mainly nuclear components
[90,91]. Of note, B cells play a central role in the pathogenesis of SLE
through the production of pathogenic auto-antibodies, immune com-
plex deposition and cytokine activation [14–19]. Multiple studies have
shown that IFN-α signaling can impact the function of B cells through
a variety of mechanisms, including class-switch recombination, TLR7
expression and differentiation [29–34]. Notably, it has been shown
that estrogens can affect the autoantibody production of B cells [92].
However, the relationships among estrogens, IFN-α signaling and auto-
antibody production in B cells are still incompletely understood. Thus,
we studied the effect of estrogen on activation of IFN-α signaling in B
cells. Given that IFN-α signaling plays a role in wide range of effects
on the immune system, including the activation of dendritic cells and
other immune cells [93], 17β-estradiol may also play roles in other im-
mune cell types that express ERα through regulating the activation of
IFN-α signaling. More studies are still need to do to explore the effect
of 17β-estradiol on activation of IFN-α signaling in ERα-expressing
cells, such as dendritic cells and macrophages.
In conclusion, 17β-estradiol can amplify IFN-α-induced signaling in
B cells viamiRNA-dependent pathways. 17β-Estradiol down-regulates
the expression of let-7e-5p, miR-98-5p and miR-145a-5p via ERα and
subsequently promotes IKKε expression. Over-expressed IKKε pro-
motes phosphorylation of STAT1 and activation of IFN-α signaling in B
cells. Our ﬁndings may provide a new perspective for understanding
the mechanism of gender difference, particularly 17β-estradiol, in the
prevalence of some autoimmune diseases.5. Conclusion
Altogether, our ﬁndings may provide a new perspective for under-
standing the mechanism of gender difference in the prevalence of SLE.Competing interests
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